Next FDA Commissioner Must Promote Competition, Transparency And Value In The Pharmaceutical Marketplace
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today ahead of a U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) executive session to consider the nomination of Dr. Robert M. Califf to serve as commissioner of the U.S. Food and Drug Administration (FDA).
“CSRxP congratulates Dr. Califf on his nomination to lead the FDA at a critical time for the agency and for the millions of Americans who face financial uncertainty affording their medications,” said CSRxP executive director Lauren Aronson. “The FDA plays a key role in holding Big Pharma accountable, supporting more affordable alternatives to high-priced brand name drugs and ensuring value for patients is factored into agency decisions.”
“The FDA has taken positive steps in recent years to support competition to help lower drug prices, including by approving more interchangeable biologic drugs,” Aronson continued. “If confirmed, CSRxP looks forward to working with Dr. Califf to build on this positive progress by promoting value, competition and transparency in the prescription drug marketplace.”
Read CSRxP’s statement on the recent FDA approval of the first interchangeable biologic for Humira HERE.
Read CSRxP’s statement on the recent FDA approval of the first interchangeable biologic for an insulin product HERE.
Learn more about solutions to hold Big Pharma accountable and lower prescription drug prices HERE.